Immatics N.V. logo
Immatics N.V. IMTX
$ 6.11 -3.02%
report update icon

Quarterly report 2025-Q4
added 11-14-2026

Immatics N.V. Market Cap | IMTX

As of November 19, 2026 Immatics N.V. has a market cap of $ 748 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Immatics N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
735 M 1.28 B 815 M 508 M 503 M - 192 M 176 M - - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
1.28 B 176 M 602 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
311 M - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
11.4 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
541 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
73.5 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
179 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
101 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
2.98 B - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
47.3 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
769 M $ 3.62 4.18 % $ 561 M usaUSA
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
1.91 B - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
109 K - -4.36 % $ 27 M usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
1.4 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
43.9 B - - $ 69.7 B britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
544 K - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
3.19 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
126 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
43.8 M - 368.57 % $ 41.9 M usaUSA
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
7.1 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
117 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
184 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
1.02 B - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
528 K - -8.77 % $ 12.4 M israelIsrael
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
122 B $ 59.5 -3.02 % $ 121 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
148 M - - $ 1.41 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
5.65 B $ 1.1 -1.79 % $ 2.71 B israelIsrael
Iterum Therapeutics Iterum Therapeutics
ITRM
28 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
851 K - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
8.96 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
450 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
17.7 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
308 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
548 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
3.35 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
48.1 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
114 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
1.08 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
39.9 M - - $ 728 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
127 M - - $ 127 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
52.7 M - - $ 155 M usaUSA
Aravive Aravive
ARAV
60.4 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
52.7 M - - $ 231 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA